GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (FRA:REG) » Definitions » Short Ratio

RemeGen Co (FRA:REG) Short Ratio


View and export this data going back to 2021. Start your Free Trial

What is RemeGen Co Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


RemeGen Co (FRA:REG) Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (FRA:REG) Headlines

From GuruFocus

Q2 2022 Regency Centers Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2021 Regency Centers Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2019 Regency Centers Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Regency Centers Corp at NAREIT REITWeek Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Regency Centers Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Regency Centers Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024